Exopharm : Appendix 4D and Half Year Report for period 31 December 2021

Half Year Financial Report

ended 31 December 2021

For personal use only

For personal use only

Exopharm Limited

Appendix 4D

Half-year report

1. Company Details

Name of entity:	Exopharm Limited
ACN:	163 765 991
Reporting period:	For the half-year ended 31 December 2021
Previous period:	For the half-year ended 31 December 2020

2. Results for announcement to the market

				$
Revenues from ordinary activities	up		to	53,260
Loss from ordinary activities after tax attributable to the owners of Exopharm	up	29%	to	(7,576,333)
Limited
Total comprehensive loss for the half-year attributable to the owners of	up	29%	to	(7,571,484)
Exopharm Limited
		31 Dec 2021	31 Dec 2020
		Cents		Cents
Basic and diluted loss per share		(4.82)	(5.06)
Diluted loss per share		(4.82)	(5.06)

Dividends

There were no dividends paid, recommended or declared during the current financial period.

Comments

The loss for the Group after providing for income tax amounted to $7,576,333 (31 December 2020: $5,866,942).

3. Net tangible assets		2021	2020
	Note
	$	$
Net tangible assets per ordinary security		0.070	0.066

4. Control gained over entities

Not applicable.

5. Loss of control over entities

Not applicable.

EXOPHARM HALF YEAR FINANCIAL REPORT ENDED 31 DECEMBER 2021

Exopharm Limited Appendix 4D Half-year report

For personal use only

6. Dividends

Current period

There were no dividends paid, recommended or declared during the current financial period.

Previous period

There were no dividends paid, recommended or declared during the previous financial period.

7. Dividend reinvestment plans

Not applicable.

8. Details of associates and joint venture entities

Not applicable.

9. Foreign entities

Details of origin of accounting standards used in compiling the report:

Not applicable.

10. Audit qualification or review

Details of audit/review dispute or qualification (if any):

The financial statements were subject to a review by the auditors and the review report is attached as part of the Interim Financial Report.

11. Attachments

Details of attachments (if any):

The Interim Financial Report of Exopharm Limited for the half-year ended 31 December 2021 is attached.

12. Signed

Signed

Date: 25 February 2022

Dr Ian E Dixon

Managing Director & CEO

Exopharm Limited

EXOPHARM HALF YEAR FINANCIAL REPORT ENDED 31 DECEMBER 2021

For personal use only

Exopharm Limited

ACN 163 765 991

Half Year Financial Report ended 31 December 2021

EXOPHARM HALF YEAR FINANCIAL REPORT ENDED 31 DECEMBER 2021

Exopharm

only	Half Year Financial Report
ended 31 December 2021
	Contents
use	02	Corporate Directory
03	Directors' Report
	10	Auditor's Independence Declaration
	09	Consolidated statement of profit or loss and other comprehensive income
personalFor	10	Consolidated statement of financial position
11	Consolidated Statement of Profit or Loss and Other Comprehensive Income
	12	Consolidated Statement of Financial Position
	13	Consolidated Statement of Changes in Equity
	14	Consolidated Statement of Cash Flows
	15	Notes to the Consolidated Financial Statements
	22	Directors' Declaration
	23	Independent Auditor's Review Report

EXOPHARM HALF YEAR FINANCIAL REPORT ENDED 31 DECEMBER 2021

1